Clinical Digest: A Comprehensive Review of Recent Astrazeneca Clinical Trials (2026-04)
This compilation provides an overview of Astrazeneca‘s recent clinical trial activity, encompassing up to 200 of their latest trials. Alongside these trials are potentially related publications, patents, and grant funding, which may include work from Astrazeneca or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Astrazeneca’s current research and development pipeline. By presenting clinical trial details alongside related intellectual property and financial backing (regardless of origin), this compilation facilitates a broader understanding of Astrazeneca’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Astrazeneca’s clinical trials. (Last updated on: 2026-04-05)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Astrazeneca Clinical Trials (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate The Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on The Risk of Incident Heart Failure and Cardiovascular Death PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites’ identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when … |
ASTRAZENECA | 2026-04-03 |
| 2 | A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician’s Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC. |
KIM NGUYEN CHI; | 2026-04-03 |
| 3 | A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate The Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure. |
ASTRAZENECA | 2026-04-03 |
| 4 | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess The Efficacy and Safety of Trastuzumab Deruxtecan As First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations |
ASTRAZENECA | 2026-04-03 |
| 5 | A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity |
ASTRAZENECA | 2026-04-03 |
| 6 | A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate The Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA. |
ASTRAZENECA | 2026-04-03 |
| 7 | PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction (PHRASE-HF): A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial. Heart failure with reduced ejection fraction (HFrEF) represents approximately 50% of the HF patient population.The burden of HF is expected to increase substantially as the population ages, and despite improvements in treatment, hospitalisation and mortality rates remain especially high in HFrEF patients. The current guideline recommendation of directed medical therapy for HFrEF combines four drug classes with proven prognostic benefit: Angiotensin receptor-neprilysin inhibitor (ARNI)/angiotensin converting enzyme inhibitors (ACE I)/angiotensin receptor blockers (ARB), betablockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The 2023 ESC (European Society of Cardiology) HF guideline update additionally recommends a rapid in-hospital sequencing approach of guideline-directed medical therapy (GDMT) with frequent physician visits during the first 6 weeks post discharge. Studies investigating the implementation of GDMT in a real-world setting have shown that a significant proportion of patients did not receive the recommended drug combination therapy. Delayed initiation of GDMT contributes to the low number of patients receiving guideline concordant HFrEF therapy, which ultimately may affect patient outcomes. One approach to implement the … |
ASTRAZENECA | 2026-04-03 |
| 8 | Open-label Single-arm, Non-interventional, Multi-centre Study for Evaluation of Clinical and Patient Reported Outcomes in Adult Patients With CRSwNP on Tezepelumab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma). |
ASTRAZENECA | 2026-04-03 |
| 9 | DAHLIA: Achievement of Low Level of Disease Activity With A Dose of Corticosteroids Less Than or Equal to 5 Mg (LLDAS5): A Real-life Study With Anifrolumab on Patients With Systemic Lupus Erythematosus in Italy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5 |
ASTRAZENECA | 2026-04-03 |
| 10 | A Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess The Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years. |
ASTRAZENECA | 2026-04-03 |
| 11 | A Phase I, Randomized, Open-label, 3 or 4-period, 7-treatment, Single-dose, Two Cohort, Crossover Study to Assess The Relative Bioavailability of Laroprovstat/Rosuvastatin Fixed Combination Drug Products to The Single Therapy Products in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults. |
ASTRAZENECA | 2026-04-03 |
| 12 | A Modular Phase I/II Open-label, Multicenter Study to Evaluate The Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL). |
ASTRAZENECA | 2026-04-03 |
| 13 | A Master Protocol Phase I/II Study to Investigate Biomarker-Guided Novel Anticancer Agent(s) As Monotherapy or Combination Therapy for The Treatment of Participants With Advanced/Recurrent Ovarian Cancer (Ovarian Platform) Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of biomarker-guided novel anticancer agent(s) as monotherapy or combination therapy for the treatment of participants with advanced/recurrent ovarian cancer. Substudy 1 will investigate the safety, tolerability, preliminary efficacy, PK and PD of saruparib monotherapy in participants with BReast CAncer gene (BRCA) mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
ASTRAZENECA | 2026-04-03 |
| 14 | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed By Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab With or Without Chemotherapy for The Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer. |
ASTRAZENECA | 2026-04-02 |
| 15 | A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. |
MARJORIE G ZAUDERER; | 2026-04-02 |
| 16 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT. |
ASTRAZENECA | 2026-04-02 |
| 17 | A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With An Open-label Extension to Evaluate The Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the ‘main study’): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to their prior stable HES background therapy, and an open-label extension (OLE) period, during which all patients will receive benralizumab. The primary database lock (DBL) will occur when approximately 38 patients have had their first HES worsening/flare event during the DB treatment period and all randomised patients have had the opportunity to be followed up for the 24-week DB treatment period. A patient must complete the 24-week DB treatment period on investigational product (IP) to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE. |
ASTRAZENECA | 2026-04-02 |
| 18 | Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting. |
JINMING YU; | 2026-04-02 |
| 19 | A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC). |
ASTRAZENECA | 2026-04-02 |
| 20 | An Open-label, Fixed Sequence Phase I Study to Evaluate The Effect of Itraconazole (a Strong CYP3A Inhibitor) on The Pharmacokinetics of AZ14170132, The TOP1 Inhibitor Payload of The Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132. |
ASTRAZENECA | 2026-04-02 |
| 21 | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing The Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone As Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised By PTEN Deficiency PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause. |
ASTRAZENECA | 2026-04-01 |
| 22 | A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids. |
ASTRAZENECA | 2026-04-01 |
| 23 | An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID OLE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of Study D5271C00002 (Legacy #3150-303-008) is to permit participants in D5271C00001 (Legacy #3150-301-008) to receive open-label brazikumab in Study D5271C00002 (Legacy #3150-303-008). This will permit long-term observation of safety in these participants with brazikumab. |
ASTRAZENECA | 2026-04-01 |
| 24 | Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up. |
ASTRAZENECA | 2026-04-01 |
| 25 | Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: An open-label, single-arm, non-interventional, prospective, multicenter study involving primary data collection within real-world settings for patients who receive benralizumab for treatment of severe uncontrolled eosinophilic asthma |
ASTRAZENECA | 2026-04-01 |
| 26 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for The First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1). |
ASTRAZENECA | 2026-03-31 |
| 27 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator’s choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC. |
ASTRAZENECA | 2026-03-31 |
| 28 | A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture The Reasons for Switch to Triple Combination Therapy and to Assess The Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic obstructive pulmonary disease (COPD) is a debilitating and progressive respiratory condition characterized by irreversible airflow limitation. The overall 5-year survival for COPD patients is 56-92%, depending on disease severity. Considering the recent introduction of the Budesonide, Glycopyrronium bromide and Formoterol fumarate Metered-Dose Inhaler (BGF MDI) in COPD therapeutic arsenal as well as the increasingly important role of real-world (RW) data in health care decisions, as it bridges gaps not addressed by randomized clinical trials, there is a need for RW evidence studies that can serve as inputs for Health Technology Assessment (HTA) submissions. In view of this need, this study is designed to generate RW evidence on the clinical and patient-reported outcomes of treatment with BGF MDI over a 52-week treatment period in routine care settings in Greece as well as to shed light on the reasons for switching from dual to triple therapy with BGF MDI, aiming at further characterizing the multifactorial aspects of inadequate COPD management that lead physicians to step-up treatment. The study is mainly descriptive in nature and is not planned to reject or affirm any formal statistical hypothesis. This is a single-country, non-interventional, multicenter, 52-week prospective cohort study, mainly based on primary data collection, … |
ASTRAZENECA | 2026-03-31 |
| 29 | Clinical and Demographic Characteristics of Adult Patients With NEurofibromatosis in RUSsia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Clinical and Demographic Characteristics of Adult Patients with NEurofibromatosis in RUSsia (NEREUS) |
ASTRAZENECA | 2026-03-31 |
| 30 | Real-World Treatment Study of Koselugo (Selumetinib) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea. This study will provide information on the Korean patient population that is treated with the study drug. |
ASTRAZENECA | 2026-03-31 |
| 31 | A Randomized, Double-blind, Multicenter, Parallel-group, Phase IIIb 52 Week Study Evaluating The Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year. |
ASTRAZENECA | 2026-03-31 |
| 32 | Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have No Satisfactory Alternative Treatment Options: A Hybrid Observational Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US |
ASTRAZENECA | 2026-03-31 |
| 33 | A Modular, Phase I, Open-label, Multicenter Study to Evaluate The Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, A Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM). |
ASTRAZENECA | 2026-03-31 |
| 34 | A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy. |
ASTRAZENECA | 2026-03-31 |
| 35 | The Eplontersen Pregnancy and Lactation Outcomes Study (EPPRO): A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and/or lactation. |
MYRIAM ALEXANDER; | 2026-03-31 |
| 36 | OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on The Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented. |
ASTRAZENECA | 2026-03-30 |
| 37 | A Multinational, Multicenter, Observational, Prospective Cohort Study for Assessing The Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking. In Turkey, COPD was ranked the third among the mortality causes and the eighth among disability causes, with 9.1% to 19.1% prevalence rate. In the Middle East and North Africa (MENA) region, an increase of 30.6% in age-standardized point prevalence occurred between 1990 and 2019, with an estimated 10.7 million COPD cases. Similarly, in the sub-Saharan Africa region, the highest COPD prevalence rate of 24.8% was observed in South Africa. And in Kenya, East Africa, the pooled point estimate prevalence of COPD was 11.3%. The prevalence of COPD varies substantially between countries, but comparing numbers is challenging because they are recorded in different units and during different periods. Patients with COPD are more likely to develop cardiovascular disease (CVD). For instance, COPD has been shown to increase the risk of acute myocardial infarction by 40% and stroke by 50%. Likewise, COPD patients with CVD have a considerably higher risk of COPD exacerbations than those without CVD. COPD and CVD have been linked to a worse prognosis primarily related to increased systemic inflammation; the presence … |
ASTRAZENECA | 2026-03-30 |
| 38 | A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess The Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy |
ASTRAZENECA | 2026-03-30 |
| 39 | Prospective Non-interventional Study (NIS) to Examine The Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need. |
ASTRAZENECA | 2026-03-30 |
| 40 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Safety and Efficacy of Nirsevimab, A Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China |
ASTRAZENECA | 2026-03-30 |
| 41 | A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC. |
ASTRAZENECA | 2026-03-30 |
| 42 | A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant DdMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting. |
ASTRAZENECA | 2026-03-30 |
| 43 | A Phase IIb, Randomized, Multicenter, Open-label Study to Assess The Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations And/or Co-mutations in STK11, KEAP1, or KRAS (TRITON) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS. |
ASTRAZENECA | 2026-03-30 |
| 44 | A Multi-center Longitudinal Observation Translational Study to Evaluate Phenotypes, Endotypes and Biomarkers in Chinese Patients With NCFBE PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disease characterized by a clinical syndrome of chronic productive cough and recurrent respiratory infections in the presence of abnormal and permanent dilation of the bronchi. Recent epidemiological studies have clearly shown that the prevalence and incidence of NCFBE are quickly rising both in high- and low-income countries. With the increase of prevalence, bronchiectasis brings huge medical and economic burden to the society. In this study, the investigator will perform biomarker assessments and multi-omics analysis on NCFBE patients and healthy participants in China to validate the link of disease pathways to pathophysiological features and uncover the molecular endotypes behind clinical phenotypesof Chinese patients with NCFBE. |
JINFU XU; | 2026-03-30 |
| 45 | A Phase I Multicentre Open-label Study to Evaluate Safety, Tolerability, and Dosimetry of [111In]-FPI-2107 in Chinese Adult Participants With EGFR Mutation-positive NSCLC PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I, multicentre, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, PD, and PK of \[111In\]-FPI-2107 after pre-dose administration of FPI-2053 in Chinese participants with EGFR mutation-positive NSCLC. |
ASTRAZENECA | 2026-03-30 |
| 46 | A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 Following Single and Multiple Ascending Doses in Participants With Dyslipidemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia. |
ASTRAZENECA | 2026-03-30 |
| 47 | An Open-label, Fixed-sequence, Two-part Study to Assess The Effect of AZD5004 on The Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants. |
ASTRAZENECA | 2026-03-30 |
| 48 | A Multinational, Observational, Retrospective, Secondary Data Study Analyzing Dapagliflozin Effectiveness in Routine Clinical Practice Among Patients With Chronic Kidney Disease. Local Adaptation for Spain. Part 2 PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD) |
ASTRAZENECA | 2026-03-27 |
| 49 | A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess The Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure |
ASTRAZENECA | 2026-03-27 |
| 50 | Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan |
ASTRAZENECA | 2026-03-27 |
| 51 | A Retrospective Study of Biliary Complications and Treatment Duration in Patients With Biliary Tract Cancer Receiving Systemic Therapy in Japan PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multi-center, retrospective, observational study of patients receiving first-line systemic therapy as routine clinical care for unresectable BTC in Japan. This study attempts to test the hypothesis that the occurrence of biliary complications requiring hospitalization during first-line systemic therapy for unresectable BTC, which is as a time-dependent covariate, affects time to treatment failure (TTF) . |
ASTRAZENECA | 2026-03-27 |
| 52 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for The First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1. |
ASTRAZENECA | 2026-03-27 |
| 53 | A Translational Study in Patients With COPD and Early COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on early COPD, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants initially for 1-year period. The follow-up period may extend up to 3 years depending upon emerging data and feasibility assessment by the sponsor. |
ASTRAZENECA | 2026-03-27 |
| 54 | TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs |
ASTRAZENECA | 2026-03-27 |
| 55 | A Phase IIIb Single Arm, 2 Cohorts Study Assessing The Efficacy and Safety of Capivasertib+ Fulvestrant As Treatment for Locally Advanced(Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With Endocrine Therapy in Chinese Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy. The Primary objective is to assess the efficacy of capi+ful by assessment of TFST (Time to first subsequent treatment) of PIK3CA/AKT1/PTEN-altered subgroup in cohort1. |
ZEFEI JIANG; | 2026-03-27 |
| 56 | A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating The Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets. |
ASTRAZENECA | 2026-03-27 |
| 57 | A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate The Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, A T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies. |
ASTRAZENECA | 2026-03-27 |
| 58 | A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels and participants with dyslipidemia. |
ASTRAZENECA | 2026-03-27 |
| 59 | A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess The Safety, Tolerability and Pharmacokinetics of AZD3974 After Single and Multiple Ascending Dosing to Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety and tolerability of AZD3974 and characterize the pharmacokinetics (PK) of AZD3974 following oral administration to healthy participants, including participants of Japanese and Chinese descent. |
ASTRAZENECA | 2026-03-27 |
| 60 | A Modular Open-label, Phase I/IIa Study to Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 As Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies. |
ASTRAZENECA | 2026-03-27 |
| 61 | A Phase 2, Multicenter, Open-label Study to Evaluate The Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for The Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ovarian cancer, and E) HER2 IHC 2+ or 1+ cervical cancer. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors. |
ASTRAZENECA | 2026-03-27 |
| 62 | A Modular Phase I, Open-label Study to Assess The Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase I modular study to assess the effect of oral saruparib on other treatments in patients with advanced solid malignancies. |
ASTRAZENECA | 2026-03-27 |
| 63 | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate The Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria |
ASTRAZENECA | 2026-03-25 |
| 64 | A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach. |
ASTRAZENECA | 2026-03-25 |
| 65 | REBECCA Real-world Early BrEast CanCer MAnagement REBECCA. A French National Multicentric Real-world Study of Early Breast Cancer Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician’s discretion. |
ASTRAZENECA | 2026-03-25 |
| 66 | A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for The First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC. |
ASTRAZENECA | 2026-03-25 |
| 67 | A Phase IIIb Study of Durvalumab As Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Lung cancer is a highly prevalent disease worldwide in women and men. In 2022, lung cancer stood as the most frequently diagnosed cancer with approximately 2.48 million new cases on a global scale, followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer is the leading cause of cancer death worldwide according to data provided by the International Agency for Research on Cancer. In 2022 they estimated a 1.8 million deaths across the world. Specifically in Spain, from 1980 to 2022, lung cancer led to 745,182 deaths. Histologically, lung cancer (LC) can be classified into two major subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), accounting for 85% and 15% of LC patients, respectively. Smoking is the major risk factor for SCLC. There are two stages of SCLC: limited-stage SCLC (LS-SCLC) and extensive-stage SCLC (ES-SCLC). Limited-stage (LS) means that the cancer is located on the ipsilateral hemithorax that can be encompassed within a radiation port while extensive-stage (ES) means that the cancer has spread widely throughout the lungs, to non-regional lymph nodes or to other organs. At present, LS is identified in \~30% of patients, and ES is identified … |
ASTRAZENECA | 2026-03-25 |
| 68 | Clinical Observational Study of Remote, Non-invasive, Multidomain Endpoints in Patients Recovering From Acute Decompensated Heart Failure PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the utility of a wearable heart monitoring patch that can be worn on the body to collect various measurements related to heart failure and develop a concept to potentially be used as a new measurement. It is crucial to test out new ways that make it easier to do research for new drugs and increase our chances of knowing how well they will work early on in the development process. Results from this study will be useful in planning future development programs for drugs aimed at treating patients with heart disease. This study will be conducted in three hospitals, it is non-randomised (not chosen by chance), exploratory, study in the United Kingdom. It aims to involve up to 80 men and women recently admitted due to sudden, severe heart failure symptoms. Participants will be part of the study for about two months, with one hospital visit after discharge, as commonly done in heart failure centres. * Visit 1 (Pre-Screening/Screening/Enrolment) will assess the participant’s eligibility for participating in the study and for collecting data following hospitalisation for acute decompensated heart failure (ADHF). Participants will be trained and receive an ECG patch to wear from that moment … |
IAIN SQUIRE; | 2026-03-25 |
| 69 | An Observational Multicenter Cross-sectional Study of Patients With Uncontrolled Severe Asthma in The Population of The Russian Federation PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics). Planned number of study site is 50 outpatient centers with experience of uncontrolled SA treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled SA in different regions in the most comprehensive way). This non-interventional study does not imply any intervention into a routine clinical practice, and does not provide for any diagnostic and therapeutic procedures other than those used in routine practice. |
ASTRAZENECA | 2026-03-24 |
| 70 | Pooled Analysis of Multi-country, Open-label Single-arm, Non-interventional, Multi-center, Cohort Studies of Real-world Outcomes in New Users of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary/primary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania. |
MICHAEL F POLLACK; | 2026-03-24 |
| 71 | A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess The Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab. |
ASTRAZENECA | 2026-03-24 |
| 72 | A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on The Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected. |
ASTRAZENECA | 2026-03-24 |
| 73 | ROSY-D: Roll Over StudY for Patients Who Have Completed A Previous Oncology Study With Durvalumab and Are Judged By The Investigator to Clinically Benefit From Continued Treatment PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. |
ASTRAZENECA | 2026-03-24 |
| 74 | Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer. |
ASTRAZENECA | 2026-03-24 |
| 75 | A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163. |
ASTRAZENECA | 2026-03-24 |
| 76 | AQUALIS: Quality of Life of Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib in France: A Retrospective Observational Study Based on Data Extracted From The PLATON Database PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting. The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting. |
ASTRAZENECA | 2026-03-24 |
| 77 | A Phase II, Multi-Center Study to Evaluate The Efficacy and Safety of Volrustomig As Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors. |
ASTRAZENECA | 2026-03-24 |
| 78 | A Non-interventional Study Evaluating Samples From Patients With Suspected Non-small Lung Cancer or Breast Cancer to Describe Pathology Practices and to Evaluate Computational Pathology Plus Artificial Intelligence Algorithms PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer. |
ASTRAZENECA | 2026-03-23 |
| 79 | A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 As Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents |
ASTRAZENECA | 2026-03-23 |
| 80 | Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Acalabrutinib received European Medicines Agency approval on November 2020 for for CLL adult patients, either as monotherapy or in combination with obinutuzumab, in previously untreated patients or as monotherapy in patients who have received at least one prior therapy and is reimbursed in Romania since January 2023. In the absence of disease registries or national datasets patient population receiving acalabrutinib in real life setting is not well characterized. The study aims to look into this population outcomes and clinical characteristics having as primary objective time to discontinuation by line of treatment and secondary objectives: reasons for discontinuation, effectiveness of acalabrutinib in real-life practice, baseline clinical and demographic characteristics, treatment patterns and major determinants of treatment discontinuation. The study will retrospectively collect longitudinal data from 250 patients at national level,at pre-defined timepoints for 3 years, from 2 sequential cohorts,1st one enrolled on December 2023 and 2nd one enrolled in December 2024 based on the acalabrutinib start year.. |
ASTRAZENECA | 2026-03-23 |
| 81 | A Phase II, Multicenter, Open-label Study to Evaluate The Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for The Treatment of Unresectable And/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted. |
ASTRAZENECA | 2026-03-23 |
| 82 | A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess The Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes). |
ASTRAZENECA | 2026-03-23 |
| 83 | A Phase III, Multicentre, International Study With A Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess The Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas. |
ALICE P. CHEN; | 2026-03-23 |
| 84 | Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab. |
ASTRAZENECA | 2026-03-23 |
| 85 | Pan HER2: A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, non-interventional, descriptive study to retrospectively collect solid tumor samples from focused tumor types (NSCLC, GYN cancers, BTC and UC) and assess both assay concordance and interpretation concordance. |
ASTRAZENECA | 2026-03-20 |
| 86 | A Multicentre, Single Arm, Non-interventional, Prospective Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy. |
CHEN WANG; | 2026-03-20 |
| 87 | A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab As First-line Treatment in Patients With Advanced Hepatocellular Carcinoma PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy |
ASTRAZENECA | 2026-03-20 |
| 88 | DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC. |
ASTRAZENECA | 2026-03-20 |
| 89 | A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study. |
ASTRAZENECA | 2026-03-20 |
| 90 | A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W). |
TANYA M LAIDLAW; | 2026-03-20 |
| 91 | A Phase III, Multicentre, Open-Label, Randomised Study Evaluating The Efficacy and Safety of R-mini-CHOP X2 Followed By AZD0486 Versus R-mini-CHOP X6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL. |
MICHAEL DICKINSON; | 2026-03-20 |
| 92 | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA). |
ASTRAZENECA | 2026-03-20 |
| 93 | A Phase I Randomized, Single-Blind, Placebo-Controlled Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 Following Single and Multiple Ascending Dose Administration in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in A Prospective, Non-interventional Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD). |
ASTRAZENECA | 2026-03-20 |
| 94 | A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate The Safety and Efficacy of Osimertinib With Amivantamab As First-line Treatment in Participants With Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). |
ASTRAZENECA | 2026-03-20 |
| 95 | EXCEED – A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide As Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an intention-to-treat approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a … |
FABIAN HOTI; | 2026-03-19 |
| 96 | A Phase III, Randomised, Double-blind Study to Evaluate The Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on The Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events. |
ASTRAZENECA | 2026-03-19 |
| 97 | A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients. |
XIAO QIANG DING; | 2026-03-19 |
| 98 | Saphnelo for Intravenous Infusion 300 Mg Specific Use Result Study All Patient Investigation in Patients With Systemic Lupus Erythematosus PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting. |
ASTRAZENECA | 2026-03-19 |
| 99 | A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1). |
ASTRAZENECA | 2026-03-19 |
| 100 | A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of AZD1613 Following Single and Multiple Dose Administration in Healthy Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent. |
ASTRAZENECA | 2026-03-19 |
| 101 | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024. |
ASTRAZENECA | 2026-03-19 |
| 102 | GYNGHER – HER2 Expression in Gynecological Malignancies: A Brazilian Cohort PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Adult patients with gynecologic cancer (endometrial, ovarian, cervical, vulvar and vaginal cancers) treated at Oncoclínicas \& CO sites will be enrolled for primary tumor immunohistochemistry (IHC) analysis. When sufficient paraffin tissue is available for biomarker testing, slides will be sent from partner Pathology Labs of the OC Precision Medicine network to Locus Lab (São Paulo) for HER2 staining with automated protocols (Dako HercepTest and Roche Ventana 4B5) and scoring using different criteria (gastric cancer, breast cancer, and endometrial cancer). Primary objective is to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in endometrial, ovarian, and cervical cancers (common gynecological malignancies). Secondary objectives are to describe the prevalence of HER2 high expression (IHC 3+ using Dako HercepTest and gastric cancer scoring criteria) in vulvar and vaginal cancers (rare gynecological malignancies); and to describe the prevalence of different HER2 expression levels (IHC 0, 1+ and 2+ using Dako HercepTest and gastric cancer scoring criteria) across all gynecological malignancies, to describe HER2 expression levels as per endometrial cancer scoring criteria in the endometrial cohort; to describe the association of different histological subtypes of gynecological cancer with HER2 IHC expression levels. |
ANGÉLICA NOGUEIRA RODRIGUES; | 2026-03-19 |
| 103 | A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate The Efficacy and Safety of Anifrolumab Administered As Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment. |
ASTRAZENECA | 2026-03-19 |
| 104 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate The Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) As Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours. |
GLOBAL CLINICAL LEAD; | 2026-03-19 |
| 105 | Pregnancy and Infant Outcomes in Anifrolumab Exposed Pregnancies Using PRegnancy Outcomes Intensive Monitoring (PRIM) Data: The Anifrolumab PRIM Program PF:3 Related Papers Related Patents Related Grants Related Experts Abstract: The anifrolumab PRIM program is a supplementary program which utilizes enhanced collection of secondary data from reported anifrolumab-exposed pregnancies collected as part of … |
SYD PHILIPS; | 2026-03-19 |
| 106 | BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate The Efficacy and Safety of Benralizumab 30 Mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting Β2-Agonist PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA. |
ASTRAZENECA | 2026-03-19 |
| 107 | Ovarian Cancer Epidemiology and Care in Brazil: A Multicenter Perspective (OLIVIA Study) Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country. |
ASTRAZENECA | 2026-03-19 |
| 108 | A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating The Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy |
ASTRAZENECA | 2026-03-19 |
| 109 | PANGEIA-2: Prevalence of Emerging Treatment-induced Mutations in MetastaticER Positive Breast Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Observational study on prevalence of emerging ESR1 mutations in liquid biopsy in two cohorts of patients with breast cancer (with and without prior therapies in metastatic setting) in comparison with patient’s baseline ESR1 mutation status as defined by tissue profiling. |
RODRIGO DIENSTMANN; | 2026-03-19 |
| 110 | Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization. |
ASTRAZENECA | 2026-03-19 |
| 111 | A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess The Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation. |
ASTRAZENECA | 2026-03-19 |
| 112 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate The Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With A History of COPD Exacerbations (MIRANDA) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment. |
ASTRAZENECA | 2026-03-18 |
| 113 | A Phase III, Multicentre, Randomised, Open-label Study to Compare The Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator’s choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL. |
CHAN CHEAH; | 2026-03-18 |
| 114 | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in The Breast And/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy. |
ASTRAZENECA | 2026-03-18 |
| 115 | A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing The Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 Mg With Fulvestrant (FASLODEX™) 250 Mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment. |
ASTRAZENECA | 2026-03-18 |
| 116 | Outcomes in Real-life After Initation Of TreatmeNt With Trixeo (Budesonide / Glycopyrronium / Formoterol), A Non-interventional, Multi-centre, Prospective Cohort Study in Italian Routine Care Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of the CHOROS ORION study is to describe patients’ clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect. |
ASTRAZENECA | 2026-03-18 |
| 117 | Post-marketing Phase IV, Multicenter, Prospective Study to Observe The Safety and Tolerability of Breztri AerosphereTM Containing A Fixed Dose Combination of Budesonide 160 Mcg/ Glycopyrronium 7.2 Mcg/ Formoterol Fumarate Dehydrate 5 Mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD. |
ASTRAZENECA | 2026-03-18 |
| 118 | A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, A Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL). |
ASTRAZENECA | 2026-03-18 |
| 119 | TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate The Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control. |
KEFANG LAI; | 2026-03-18 |
| 120 | An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate The Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. |
ASTRAZENECA | 2026-03-18 |
| 121 | A Phase IIIb, Open-label, Multinational Study Assessing The Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer. |
ASTRAZENECA | 2026-03-18 |
| 122 | A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate The Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase IV, prospective, open-label, multicentre study to evaluate the safety of palivizumab IM injection for the prevention of severe LRTD in Indian infants and children who are at high-risk of RSV disease. All enrolled participants will receive palivizumab 15 mg/kg IM injection once a month for up to 5 injections during the study. Children who undergo cardiac surgery with cardiopulmonary bypass during the study should receive an additional dose of study intervention immediately after surgery, when medically stable for IM injection as determined by the physician. Prior to each study intervention administration, all participants will undergo safety assessments. A follow-up visit will be performed telephonically with the parent(s) or legal guardian(s) of all participants 30 days after their last injection of palivizumab. |
ASTRAZENECA | 2026-03-18 |
| 123 | A Phase I/IIa, Open-label, Multi-centre Study to Assess The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring A KRASG12D Mutation (ALAFOSS-01) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation. |
ASTRAZENECA | 2026-03-18 |
| 124 | A Phase II, Open-label, Multicentre, Single-arm Study of Durvalumab Plus Oleclumab in Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy (LADOGA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), who have not progressed following platinum-based concurrent or sequential chemoradiotherapy (cCRT or sCRT). |
ASTRAZENECA | 2026-03-18 |
| 125 | A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression. |
ASTRAZENECA | 2026-03-18 |
| 126 | Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population): Understanding The Burden of Severe Exacerbations of COPD and The Association Between Frequency of Severe Exacerbations and Clinical and Health-care Utilization Outcomes in Less Well-resourced Countries: Sample of Egyptian Patients Related Papers Related Patents Related Grants Related Experts Highlight: Chronic obstructive pulmonary disease (COPD) is a common, progressive disease characterized by airflow obstruction which is not fully reversible. Acute exacerbations of COPD (AECOPD) are described as worsening of COPD symptoms (breathlessness, cough, and sputum volume and purulence) beyond normal day to day variation. Between 30-50% of patients with COPD experience at least one AECOPD per year (1). Even a single moderate AECOPD increases risk of future multiple AECOPD events, starting a spiral of excessive disease progression and leading to an increased risk of death (2). AECOPDs have also been associated with other clinical outcomes such as accelerated lung function decline. Studies have shown that AECOPDs are related to future AECOPDs, however, little is known about clinical burden and health care utilization in the COPD population. To date, most of published literature reports a combined category of moderate-severe exacerbations, typically stratifying patients as experiencing frequent (i.e., two or more events per patient-year) vs. infrequent (none or one) exacerbations. In Egypt, COPD is considered one of the most burdensome chronic diseases, with acute exacerbations being directly associated with its burden on patients ‘lives. Although no official epidemiological data is available for COPD, its prevalence in Egypt was estimated to be 3.5% … |
ASTRAZENECA | 2026-03-18 |
| 127 | Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy As A First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC. |
ASTRAZENECA | 2026-03-17 |
| 128 | A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate The Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease. |
DAVE SINGH; | 2026-03-17 |
| 129 | A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine The Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%. |
ASTRAZENECA | 2026-03-17 |
| 130 | Real-world, International, Multicentre, Non-interventional, Prospective Cohort to Assess Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo in Routine Care Settings PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI/TRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life. The iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations |
ASTRAZENECA | 2026-03-17 |
| 131 | Multicenter, Observational, Descriptive Study of The Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: A Registry Study With Retrospective and Prospective Components PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Multicenter, observational, descriptive study of the diagnosis, course and treatment of patients with SLE in routine practice in Kazakhstan: a registry study with retrospective and prospective components. |
ASTRAZENECA | 2026-03-17 |
| 132 | A Study to Evaluate The Accuracy of Primary Care Diagnosis Using Oscillometry and Fractional Exhaled Nitric Oxide for Asthma and COPD Versus Specialist Diagnosis in Patients With Suspected Asthma or COPD PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry. While spirometry is a foundational tool, its diagnostic accuracy is often limited by the patient’s ability to perform forceful breathing maneuvers, as well as technical and reproducibility challenges, and the need for proper equipment and training. These constraints can compromise effective diagnosis of asthma and COPD in primary care settings. Prompt and accurate diagnosis by primary care physicians is essential for better patient outcomes. Although variable airflow limitation often measured as a change in FEV1 after bronchodilator is a hallmark of asthma, inconsistencies in test quality and reversibility criteria create challenges in distinguishing asthma from COPD. These complexities highlight the need for alternative diagnostic tools beyond traditional spirometry. This observational study is designed to evaluate the diagnostic accuracy and technical feasibility of using oscillometry and FeNO testing in primary care for suspected asthma and COPD, compared to conventional specialist-based diagnostics. The study will be conducted across 6 countries in the MEA, Asia, and Latin America, with two hospital sites per country. Primary care physicians will be trained in oscillometry and FeNO testing using standardized protocols and tools such as the Ambulatory Lung … |
ASTRAZENECA | 2026-03-17 |
| 133 | A Randomized, Double-blind, Multicentre, Event-driven, Parallel Group, Phase III Study Evaluating The Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Symptomatic Chinese Adults With Asthma (BAIYUN) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma. |
ASTRAZENECA | 2026-03-17 |
| 134 | A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab in this indication. Moreover, generation data on the safety and real world effectiveness of durvalumab after concurrent chemo-radiation therapy (cCRT) and subsequent chemo-radiation therapy (sCRT) in routine practice in the Russian Federation will be of high relevance. The other important question that needs to be addressed is the duration of treatment with durvalumab and its’ influence on the relevant outcomes. According to the Russian label, it is possible to continue treatment with durvalumab until disease progression, although current data from the PACIFIC trial provide the results on 12 months duration of durvalumab treatment. The real-world data about the duration of treatment with durvalumab in the Russian population and its’ influence on various outcomes would be very important. Among other goals, the current study is aimed to analyze factors influencing the effectiveness of durvalumab therapy in the real-world setting (e.g. duration of treatment, delays in the start of treatment with durvalumab after CRT over, early discontinuation due to any factors including AEs, etc.). The study also aims to … |
ASTRAZENECA | 2026-03-17 |
| 135 | External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (ESPERANZA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: In DESTINY-Pan-Tumor \[DP-02\], DESTINY CRC02 \[DC-02\], and DESTINY-Lung01 \[DL-01\], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients. This study will use real-world data (RWD) to identify IHC3+ patients in the real world who received standard of care (SoC) and compare them with IHC3+ patients who received T-DXd in the referent trials. The tumors included are: non-small cell lung cancer \[NSCLC\], colorectal cancer \[CRC\], endometrial cancer, bladder cancer, epithelial ovarian cancer, cervical cancer, pancreatic cancer, biliary tract cancers, and other tumors. This is a real-world external control arm (ECA) study to generate evidence on the comparative effectiveness of T-DXd versus real-world (RW) SoC in adult patients with HER2 IHC3+ solid tumors who have received prior systemic treatment. HER2 IHC3+ patients who initiated 5.4mg/kg of T-DXd in the referent trials (DP-02, DC-02, and DL-01) will be compared against IHC3+ patients who received RW SoC. This will be a retrospective observational study which will use secondary real-world data and data collected in the 3 aforementioned trials. Objectives: The primary objective of this study is to evaluate the comparative effectiveness with respect to overall survival (OS) for T-DXd vs SoC for patients with HER2 IHC3+ expressing solid … |
ASTRAZENECA | 2026-03-17 |
| 136 | A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate The Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2. |
ASTRAZENECA | 2026-03-17 |
| 137 | A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate The Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, A CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors |
ASTRAZENECA | 2026-03-17 |
| 138 | An Open-label, Phase I Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2. |
ASTRAZENECA | 2026-03-17 |
| 139 | A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275. |
ASTRAZENECA | 2026-03-17 |
| 140 | A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess The Effect of AZD0780 in Combination With Rosuvastatin on Low Density Lipoprotein Cholesterol in Participants With Dyslipidaemia (LAZURE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a study to investigate the effect of AZD0780 tablets on low density lipoprotein cholesterol levels (LDL-C) compared with placebo tablets administered in combination with rosuvastatin tablets in adult Russian participants with dyslipidaemia. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to 136 days, including a screening period of up to 14 days, rosuvastatin run-in period of 28 days, treatment with AZD0780 or placebo for 84 days, and a safety follow-up period of 10 days. |
ASTRAZENECA | 2026-03-17 |
| 141 | A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate The Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator. |
ASTRAZENECA | 2026-03-17 |
| 142 | A Phase II, Multicentre, Open-label, Single-arm Study of AZD0901 Monotherapy in Second-or Later-Lines Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2. |
ASTRAZENECA | 2026-03-17 |
| 143 | An Ambispective Observational Multicenter Registry of Patients With Uncontrolled Asthma in The Population of The Russian Federation PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multi-centre, non-interventional, observational, ambispective registry. Planned study population consists of 9 000 adult patients with uncontrolled asthma receiving treatment according to standard of care (except biologics). Planned number of study site is 70 outpatient centers with experience of uncontrolled asthma treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled asthma in different regions in the most comprehensive way). |
ASTRAZENECA | 2026-03-16 |
| 144 | The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases -A Multi-center, Prospective, Interventional Study (PRECEDE) PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF). |
ASTRAZENECA | 2026-03-16 |
| 145 | A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) As Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT). |
ASTRAZENECA | 2026-03-16 |
| 146 | A Multicenter, Prospective Cohort Study in Patients With Myasthenia Gravis in China PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027. |
FUDONG SHI; | 2026-03-16 |
| 147 | Asthma Control in Severe Asthma Patients Treated With Tezepelumab: A Prospective, Observational, Real-World Evidence Study (ASCENT) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A study involving primary data collection within real-world settings of participants who initiate treatment with tezepelumab for severe uncontrolled asthma. This study will complement evidence obtained from randomized controlled trials and provide new data focusing on the holistic and patient reported outcome (PRO). |
ASTRAZENECA | 2026-03-16 |
| 148 | Clinical and DEmographic ChaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in Moscow PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow |
ASTRAZENECA | 2026-03-16 |
| 149 | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for The First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations. |
SURESH S. RAMALINGAM; | 2026-03-16 |
| 150 | PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users): The AstraZeneca Pregnancy Study for Anifrolumab PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement. |
ASTRAZENECA | 2026-03-16 |
| 151 | A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn’s Disease and An Ileostomy (CALLISTO) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn’s disease and an ileostomy. |
ASTRAZENECA | 2026-03-16 |
| 152 | GRANITE: Airsupra Effectiveness in The Real World A Retrospective Prevalent New-user Cohort Study to Describe Characteristics and Compare Effectiveness of Airsupra Vs Albuterol, in Patients With Asthma Requiring Use of Rescue Therapy in A Real-world Setting in The United States PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The GRANITE study aims to evaluate the effectiveness of Airsupra versus albuterol in reducing asthma exacerbation risk in a real-world US population. |
ASTRAZENECA | 2026-03-13 |
| 153 | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate The Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With A History of Exacerbations (PROSPERO) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD. |
ASTRAZENECA | 2026-03-13 |
| 154 | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for The First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements). |
ASTRAZENECA | 2026-03-13 |
| 155 | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine The Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer |
ASTRAZENECA | 2026-03-13 |
| 156 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine The Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions. |
ASTRAZENECA | 2026-03-13 |
| 157 | A Multicenter Non Interventional Single Arm Retrospective-prospective Observational Study in Therapeutic Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis (gMG) in Real Clinical Practice in Russia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia. |
ASTRAZENECA | 2026-03-13 |
| 158 | A Multicenter, Randomized, Parallel-group, Double-blind,Two-arm Phase III Study to Evaluate The Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud’s phenomenon symptom. |
ASTRAZENECA | 2026-03-13 |
| 159 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck Previously Treated With An Immune Checkpoint Inhibitor PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer |
ROGER B COHEN; | 2026-03-13 |
| 160 | Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab. |
ASTRAZENECA | 2026-03-13 |
| 161 | LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study in Patients With BRCA Mutated HER2 Negative High Recurrent Risk Breast Cancer in The Adjuvant Setting PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use. |
ASTRAZENECA | 2026-03-13 |
| 162 | A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Low Unresectable And/or Metastatic Breast Cancer PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Planned study population consists of approximately 3,150 adult patients with HER2-negative (IHC 0, + or IHC2+/ISH-) unresectable or metastatic BC enrolled to the study in order to obtain approximately 2,000 patients with confirmed HER2 low status (IHC1+ or IHC2+/ISH ). |
ASTRAZENECA | 2026-03-12 |
| 163 | Implementation of A Lung Cancer Screening Program in A Public Service, Using Low-dose Tomography and Metabolomics Evaluation PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service. |
ERICA N HASIMOTO; | 2026-03-12 |
| 164 | A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for The First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician’s choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer |
ASTRAZENECA | 2026-03-12 |
| 165 | A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 As Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed. |
ASTRAZENECA | 2026-03-12 |
| 166 | DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab Vs Chemotherapy Plus Pembrolizumab As First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC. |
ASTRAZENECA | 2026-03-12 |
| 167 | A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) |
ASTRAZENECA | 2026-03-12 |
| 168 | A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, A Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM. |
ASTRAZENECA | 2026-03-12 |
| 169 | An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children \<18 years of age. Approximately 140 participants will enter CP at approximately 46 sites in locations including but not limited to Europe and North America for this study. Treatment will include 3 phases: the CP, MP, and LTMP. Enrolment will start in 2 cohorts, ages 6 to \< 12 years and 12 to \< 18 years. After review of accumulated data, the independent Data Monitoring Committee (iDMC) will recommend whether to open enrolment in the ages 2 to \< 6 years cohort and later in the ages 0 to \< 2 years cohort. All eligible participants with hyperkalaemia will enter an open-label Correction Phase (CP) receiving a fixed dose of SZC three times daily (TID) for up to 3 days until normokalaemia is achieved. Within each age cohorts 2 to \< 18 years, initial participants will be allocated to the dose level (DL) based on body weight equivalent to an adult 5 ... |
ASTRAZENECA | 2026-03-12 |
| 170 | The EVOLVE Study: A Prospective, Observational Study to Evaluate Patient-centered Outcomes Over 2 Years of Treatment With Tezepelumab in Real-life Clinical Practice in Greece PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tezepelumab is a first-in-class human monoclonal antibody for uncontrolled severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), a key epithelial cytokine inducing both Type 2 and non- Type 2 inflammatory pathways. Considering the recent addition of tezepelumab to the severe asthma therapeutic arsenal, there is a need for real-world evidence that can inform treatment-decision making in clinical practice and support regulatory decisions. EVOLVE is a prospective, observational study designed to generate real-world evidence on patient-reported outcomes of treatment with tezepelumab, assessing the effectiveness over a 2-year period in routine care settings in Greece. The study plans to enroll 150 adult patients at an allocation ratio of: i) 70 percent Type 2-high/30 percent Type 2-low, and ii) 80 percent biologic naïve/20 percent switching from a prior biologic. Eligible patients must be newly prescribed tezepelumab according to the approved label. Primary data will be collected at enrollment and 4, 12, 24, 52, 72 and 104 weeks after treatment initiation through visits as per the standard clinical practice in various healthcare settings (20-25 sites) across the country. The primary objective is to describe the patient-reported asthma symptom control using the Asthma Control Questionnaire (ACQ-6) … |
ASTRAZENECA | 2026-03-12 |
| 171 | A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess The Potential for Tezepelumab-treated Patients With Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W). |
ASTRAZENECA | 2026-03-12 |
| 172 | Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant genetic disorder that is caused by germline mutations in the NF1 tumour suppressor gene, which encodes the tumour suppressor protein neurofibromin 1. Plexiform neurofibromas (PN) are histologically benign nerve sheath tumours, which typically grow along large nerves and plexi. On 5 March 2020, a centralised Marketing Authorisation Application was submitted to the European Medicines Agency (EMA), Marketing Authorisation in EU was granted on 17 Jun 2021. As part of the approval process, a Risk Management Plan (RMP) was developed and submitted to the EMA to summarise the safety concerns emerging from the clinical development program. The RMP included additional pharmacovigilance plans for a noninterventional Post-authorisation Safety Study (PASS) to further characterise the safety of selumetinib in paediatric patients with NF1-related PN in routine clinical practice. The planned non-interventional PASS will address gaps in knowledge identified by the RMP, including the important identified risk and some of the potential risks and missing information on long-term developmental toxicity in children, by characterising the safety profile associated with selumetinib use among paediatric patients (age d 8 to \< 18 years old) with a diagnosis of NF1 with symptomatic, inoperable PN. This study is a ... |
ASTRAZENECA | 2026-03-12 |
| 173 | Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice. |
ASTRAZENECA | 2026-03-12 |
| 174 | A Phase I, Randomized, Single-dose, 3-Period, Open-Label Study to Assess The Pharmacokinetic Formulation Bridging, Safety, and Food Effect of Different Oral Formulations of AZD5004 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the pharmacokinetics (PK), safety and tolerability of different oral formulations of AZD5004, and to evaluate the effect of food on these formulations in healthy participants. |
ASTRAZENECA | 2026-03-12 |
| 175 | A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate The Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers). |
ASTRAZENECA | 2026-03-12 |
| 176 | A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess The Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD). |
ASTRAZENECA | 2026-03-12 |
| 177 | Phase I Study to Compare The Pharmacokinetics of Budesonide and Formoterol Delivered With Symbicort Aerosphere® and Symbicort® PMDI in Children 4 to Less Than 12 Years of Age With Asthma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years. |
ASTRAZENECA | 2026-03-12 |
| 178 | A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy As First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL) |
ASTRAZENECA | 2026-03-11 |
| 179 | A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer. |
TINA CASCONE; | 2026-03-11 |
| 180 | Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). Advanced usually means that the cancer keeps growing even with treatment. The cancer may also be metastatic, which means that it has spread to other parts of the body or the surrounding tissue. The study drug, Datopotamab deruxtecan, is designed to work by attaching to the tumor cells and stopping the tumor growth. Datopotamab deruxtecan is also known as Dato-DXd. In this study, the researchers want to find out how well Dato-DXd works to stop tumors from growing in Chinese participants with NCSLC or TNBC. This is the first time Dato-DXd is being studied in Chinese population. Participants in this study will get Dato-DXd through a needle as an injection. They will get 1 dose of Dato-DXd every 3 weeks until their cancer gets worse or they leave the study for another reason. Participants will visit their study sites at least once every 3 weeks for as long as they are in the study. The study doctors will take blood samples every 3 weeks and take images of the participants’ tumors every 6 weeks until the participant leaves the study. |
ASTRAZENECA | 2026-03-11 |
| 181 | A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population |
ASTRAZENECA | 2026-03-11 |
| 182 | A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve. |
ASTRAZENECA | 2026-03-11 |
| 183 | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone As First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage. |
NOEL CLARKE; | 2026-03-11 |
| 184 | A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate The Efficacy and Safety of Anifrolumab in Adults With Chronic And/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory And/or Intolerant to Antimalarial Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE). |
ASTRAZENECA | 2026-03-11 |
| 185 | A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate The Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period. |
MARIO CASTRO; | 2026-03-11 |
| 186 | A Phase II, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate The Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With A History of COPD Exacerbations and Elevated Eosinophils (COMETA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or placebo administrations in participants with symptomatic chronic obstructive pulmonary disease (COPD) with history of exacerbations and high blood eosinophil counts. Study details include the following: * The maximum duration of the screening/run-in period is 5 weeks. An additional unscheduled visit may be performed prior to randomization to repeat safety assessments as deemed necessary by the investigator. * Eligible patients will enter 12-week treatment (intervention) period with site visits and investigational product (IP) administration every 2 weeks. * Participants who complete a treatment period, and have not been prematurely discontinued from IP, will enter a 10-week post-intervention follow-up period. * The study duration will be 27 weeks at maximum for each participant. |
ASTRAZENECA | 2026-03-11 |
| 187 | Specific Use-results Study of IMJUDO Intravenous Infusion 25 Mg, 300 Mg / IMFINZI Intravenous Infusion 120 Mg, 500 Mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This investigation will be conducted to collect information of safety in patients with unresectable hepatocellular carcinoma (HCC) treated with the combination therapy of IMJUDO 25 mg, 300 mg and IMFINZI Intravenous Infusion 120 mg, 500 mg or with IMFINZI monotherapy under actual use in the post-marketing setting. |
ASTRAZENECA | 2026-03-10 |
| 188 | Chronic Kidney Disease Registry Platform Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical characteristics, diagnostic and treatment patterns, and clinical outcomes of patients with chronic kidney disease (CKD), to describe the current status of the diagnosis and treatment of patients with CKD and the gaps from the diagnostic and treatment guidelines, explore the risk factors for disease progression and clinical outcomes in CKD patients, and construct a risk prediction model for CKD progression and clinical outcomes |
BICHENG LIU; | 2026-03-10 |
| 189 | A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab As First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). |
ASTRAZENECA | 2026-03-10 |
| 190 | Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup. |
ASTRAZENECA | 2026-03-10 |
| 191 | A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). |
ASTRAZENECA | 2026-03-10 |
| 192 | Understanding Non-small Cell Lung Cancer (NSCLC) Patient Characteristics, Treatment Patterns and Outcomes Via Cross-sEctional Physicians SuRvey-based Chart Audit PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among a NSCLC patients receiving at least 1L SACT (Systemic anticancer therapy) |
ASTRAZENECA | 2026-03-10 |
| 193 | A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides Difficile Infection in Individuals 18 Years of Age and Above PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above. |
ASTRAZENECA | 2026-03-10 |
| 194 | A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in The First-line Setting Through The UK Early Access Programme: Early Access Programme Outcomes In ACalabrutinib (EPIC) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients’ clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP. |
TOBY A EYRE; | 2026-03-10 |
| 195 | A Phase II, Open Label, Randomised, Multi-centre Study to Assess The Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in The Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified By Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. … |
ANDREW TUTT; | 2026-03-10 |
| 196 | Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This survey will be conducted to investigate the status of occurrence of the safety specifications set for Safety specification in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions. |
ASTRAZENECA | 2026-03-10 |
| 197 | Non-interventional Cohort Study of Patients Previously Untreated or First-generation BTKi Intolerant With Chronic Lymphocytic Leukemia Describing The First-line Use of Acalabrutinib and Its Real-world Outcomes in Spain: The PICAROS Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter non-interventional study (NIS) on patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit in Spain |
ASTRAZENECA | 2026-03-10 |
| 198 | A Master Protocol of An Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations As Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease. |
ASTRAZENECA | 2026-03-10 |
| 199 | Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients Multicountry, Multicenter, Observational, Prospective, Primary Data, Real-world Settings PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, and Qatar), Latin America (Brazil, Argentina, and Colombia), and India. It is anticipated that the data generated will provide practical, patient-focused real-world evidence and enhance communications between patients and physicians in an objective and structured manner to ensure better disease control in patients under benralizumab treatment. |
ASTRAZENECA | 2026-03-10 |
| 200 | ItAlian, Multicenter, Observational, Prospective STudy to Evaluate The AcHievement of Clinical REmission and ImmuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab – The ATHENA Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission. |
ASTRAZENECA | 2026-03-10 |